Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib

Authors:

LSLecia V. Sequist
Lecia V. Sequist

Open Access

Publisher website

Google Scholar

1 April 2016

journal article
research article
Published by American Medical Association (AMA) in JAMA Oncology

Vol. 2 (4) , 541-543
DOI:10.1001/jamaoncol.2015.5009
PMID:26720284

Abstract

Third-generation EGFR tyrosine kinase inhibitors (TKIs) that block activating EGFR mutations and the T790M resistance mutation yield marked responses among patients with EGFR mutation–positive lung cancer and acquired resistance to initial TKIs.¹^,2 Osimertinib (formerly AZD9291) was recently approved by the US Food and Drug Administration, and rociletinib (formerly CO-1686) is under regulatory consideration. Little is known about using third-generation EGFR inhibitors sequentially.

Keywords

This publication has 1 reference indexed in Scilit:

Faculty Opinions recommendation of Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor.
2015